BCL9 and prostate carcinoma: Genetic analysis of large prostate cancer datasets has revealed that several co-activators of β-catenin-mediated transcriptional activity are amplified in prostate cancer, such as BCL9 and PYGO2 (Table 1) [64,65,66].